Skip to product information
1 of 1

GeneBio Systems

CHRD Polyclonal Antibody

CHRD Polyclonal Antibody

SKU:E-AB-18617

Regular price €490,95 EUR
Regular price Sale price €490,95 EUR
Sale Sold out
Shipping calculated at checkout.

Size: 200μL

Storage: Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles.

Shipping: The product is shipped with ice pack,upon receipt,store it immediately at the temperature recommended.

Exp date: 12 months

Category ID_II: Primary Antibodies

Category ID_III: Polyclonal Antibodies

Abbreviation: CHRD

Target Synonym: Chordin;chrd;CHRD;MGC133038;Shortgastrulation protein;SOG

Research Areas: Developmental Biology;Neuroscience;Stem Cells

Conjugation: Unconjugated

Host: Rabbit

Species reactivity: Human;Mouse;Rat

Application: IHC

Isotype: IgG

Clonality: Polyclonal

Clone NO.:

UNIProt ID: Q9H2X0

Accession:

Background: CHRD (Chordin) is a Protein Coding gene. Diseases associated with CHRD include Cornelia De Lange Syndrome. Among its related pathways are Mesodermal Commitment Pathway and TGF-beta signaling pathway (KEGG). GO annotations related to this gene include heparin binding and syndecan binding. An important paralog of this gene is CHRDL2.This gene encodes a secreted protein that dorsalizes early vertebrate embryonic tissues by binding to ventralizing TGF-beta-like bone morphogenetic proteins and sequestering them in latent complexes. The encoded protein may also have roles in organogenesis and during adulthood. It has been suggested that this gene could be a candidate gene for Cornelia de Lange syndrome. Reduced expression of this gene results in enhanced bone regeneration. Alternative splicing results in multiple transcript variants. Other alternative splice variants have been described but their full length sequence has not been determined.

Concentration: 0.8 mg/mL

Immunogen: Fusion protein of human CHRD

Buffer: PBS with 0.05% NaN3 and 40% Glycerol,pH7.4

Purification method: Antigen affinity purification

Dilution: IHC 1:30-1:150

Calculated MW:

ObservedMW:

View full details